摘要

OBJECTIVE:Pancreatic cancer-associated diabetes (PCDM) is a paraneoplastic phenomenon accounting for 1% of new-onset diabetes. We aimed to identify the mediators of PCDM and evaluate their usefulness in distinguishing PCDM from type 2 diabetes.
RESEARCH DESIGN AND METHODS:Secreted proteins of MIA PaCa-2 cells were identified by proteomics, and those with ≥10-fold overexpression in transcriptome analysis were assessed by bioinformatics and glucose uptake assay to identify candidate factors. Expression of factors was compared between tumors with and without PCDM by immunohistochemistry. Serum levels were measured in a training set including PC with and without PCDM, type 2 diabetes, pancreatitis, other pancreatic/peripancreatic tumors, and control subjects (n = 50 each). Cutoff values for differentiation between PCDM and type 2 diabetes from the training set were validated in a test set (n = 41 each).
RESULTS:Galectin-3 and S100A9 were overexpressed in tumors with PCDM and dose-dependently suppressed insulin-stimulated glucose uptake in C2C12 myotubes. In the training set, serum galectin-3 and S100A9 levels were exclusively increased in patients with PCDM and distinguished PCDM from type 2 diabetes (area under the curve [AUC] galectin-3: 0.73 [95% CI 0.64-0.83]; S100A9: 0.79 [95% CI 0.70-0.87]). Similar results were observed in the test set (AUC galectin-3: 0.83 [95% CI 0.74-0.92]; S100A9: 0.77 [95% CI 0.67-0.87]), with sensitivity and specificity 72.1% and 86.1%, respectively, for galectin-3 and 69.8% and 58.1% for S100A9 in differentiating between PCDM and type 2 diabetes.
CONCLUSIONS:Galectin-3 and S100A9 are overexpressed in PCDM tumors and mediate insulin resistance. Galectin-3 and S100A9 distinguish PCDM from type 2 diabetes in subjects with new-onset diabetes.

译文

目的: 胰腺癌相关糖尿病 (PCDM) 是一种副肿瘤现象,占新发糖尿病的 1%。我们的目的是确定 PCDM 的介质,并评估它们在区分 PCDM 和 2 型糖尿病中的有用性。
研究设计和方法: 通过蛋白质组学鉴定 MIA PaCa-2 细胞的分泌蛋白,并通过生物信息学和葡萄糖摄取试验评估转录组分析中过表达 ≥ 10 倍的蛋白,以确定候选因子。通过免疫组织化学比较有 PCDM 和没有 PCDM 的肿瘤之间的因子表达。在包括有或没有 PCDM 、 2 型糖尿病、胰腺炎、其他胰腺/胰腺周围肿瘤的 PC 训练集中测量血清水平,并控制受试者 (每个 n = 50)。在测试集中验证了训练集中 PCDM 和 2 型糖尿病之间的区分截断值 (每个 n = 41)。
结果: Galectin-3 和 S100A9 在患有 PCDM 的肿瘤中过表达,并剂量依赖性地抑制 C2C12 肌管中胰岛素刺激的葡萄糖摄取。在训练集中,PCDM 患者的血清 galectin-3 和 S100A9 水平仅增加,并将 PCDM 与 2 型糖尿病区分开来 (曲线下面积 [AUC] galectin-3: 0.73 [95% CI 0.64-0.83]; S100A9: 0.79 [95% CI 0.70-0.87])。在测试集中观察到相似的结果 (AUC galectin-3: 0.83 [95% CI 0.74-0.92]; S100A9: 0.77 [95% CI 0.67-0.87]), galectin-3 的敏感性和特异性分别为 72.1% 和 86.1%,S100A9 的敏感性和特异性分别为 69.8% 和 58.1%,用于鉴别 PCDM 和 2 型糖尿病。
结论: Galectin-3 和 S100A9 在 PCDM 肿瘤中高表达,介导胰岛素抵抗。Galectin-3 和 S100A9 在新发糖尿病受试者中区分 PCDM 和 2 型糖尿病。

Galectin-3

心血管 心肌纤维化的独立指标 临床研究术语
概述  :  

Galectin-3(半乳糖凝集素-3)是一种在体内广泛分布的具有多种生物学功能的蛋白,是一种强大的炎症信号分子,参与炎性反应与纤维化过程,参与细胞黏附、增殖及调亡等过程,为心肌纤维化的独立指标。 生物学特征 Galectin-3是动物半乳糖凝集素家族中的成员之一,通过分析其分子进化特点,有研究者猜想其早在寒武纪时代就已经存在。它是一种蛋白质,并具有多种功能,在不同的组织、细胞中,如在上皮、巨噬、成纤维等细胞中都有表达,可见其分布十分广泛。14种半乳糖凝集素组成了动物凝集素家族,它

Galectin

释义   半乳凝素

短语   mouse Galectin 小鼠半乳糖凝集素

galectin family 半乳糖凝集素家族

例句   Objective: To express and purify the fusion protein of galectin-1. 目的:表达和纯化半乳糖凝集素-1融合蛋白。

请扫描右侧二维码,免费查看词汇专业知识背景